Takeda Announces Abstracts For ADCETRIS® (Brentuximab Vedotin) In Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma And Ixazomib In Multiple Myeloma To Be Presented At 56th American Society of Hematology Annual Meeting

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) today announced that abstracts of interest from studies on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin) and the investigational oral proteasome inhibitor, ixazomib (MLN9708), are among those that have been accepted for presentation at this year’s American Society of Hematology (ASH) annual meeting to be held December 6-9, 2014 in San Francisco, California.

Help employers find you! Check out all the jobs and post your resume.